38.23
price up icon0.71%   0.27
after-market Handel nachbörslich: 38.23
loading
Schlusskurs vom Vortag:
$37.96
Offen:
$38.14
24-Stunden-Volumen:
819.90K
Relative Volume:
0.66
Marktkapitalisierung:
$2.93B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-13.95
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
+14.36%
1M Leistung:
+21.44%
6M Leistung:
-1.75%
1J Leistung:
-0.05%
1-Tages-Spanne:
Value
$37.32
$38.50
1-Wochen-Bereich:
Value
$32.78
$38.50
52-Wochen-Spanne:
Value
$26.74
$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name
Firmenname
Xenon Pharmaceuticals Inc
Name
Telefon
(604) 484-3300
Name
Adresse
200 - 3650 GILMORE WAY, BURNABY
Name
Mitarbeiter
327
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
XENE's Discussions on Twitter

Vergleichen Sie XENE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
XENE
Xenon Pharmaceuticals Inc
38.23 2.93B 13.17M -199.06M -156.53M -2.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.79 100.07B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.41 59.99B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
448.91 58.03B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
653.83 39.93B 3.06B 1.28B -614.78M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
321.36 36.82B 3.81B -644.79M -669.77M -6.24

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-07 Eingeleitet Chardan Capital Markets Buy
2025-02-11 Eingeleitet Deutsche Bank Buy
2024-10-10 Fortgesetzt Raymond James Outperform
2024-10-01 Eingeleitet H.C. Wainwright Buy
2024-01-04 Eingeleitet Citigroup Buy
2023-12-08 Eingeleitet Robert W. Baird Outperform
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-04-25 Eingeleitet Cantor Fitzgerald Overweight
2022-12-14 Eingeleitet Goldman Buy
2022-12-12 Eingeleitet Cowen Outperform
2022-11-28 Eingeleitet Wells Fargo Overweight
2022-10-19 Eingeleitet Raymond James Outperform
2022-08-29 Eingeleitet BofA Securities Buy
2022-07-21 Eingeleitet JP Morgan Overweight
2021-10-28 Eingeleitet RBC Capital Mkts Outperform
2020-10-02 Eingeleitet SVB Leerink Outperform
2020-07-21 Eingeleitet Needham Buy
2020-06-01 Fortgesetzt Jefferies Buy
2020-03-25 Eingeleitet Wedbush Outperform
2020-01-08 Eingeleitet William Blair Outperform
2019-09-20 Eingeleitet Guggenheim Buy
2018-08-08 Bestätigt Stifel Buy
2017-03-13 Eingeleitet Jefferies Buy
2016-10-21 Eingeleitet Stifel Buy
2016-09-26 Eingeleitet Guggenheim Buy
2016-04-14 Bestätigt Jefferies Buy
2015-10-30 Fortgesetzt Jefferies Buy
2014-12-02 Eingeleitet Canaccord Genuity Buy
Alle ansehen

Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten

pulisher
04:40 AM

Should you wait for a breakout in Xenon Pharmaceuticals Inc.Treasury Yields & Real-Time Stock Entry Alerts - Newser

04:40 AM
pulisher
04:14 AM

Research Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World

04:14 AM
pulisher
01:17 AM

HC Wainwright Issues Negative Outlook for XENE Earnings - Defense World

01:17 AM
pulisher
Aug 14, 2025

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

Will a bounce in Xenon Pharmaceuticals Inc. offer an exitJuly 2025 Movers & Community Verified Swing Trade Signals - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Identifying reversal signals in Xenon Pharmaceuticals Inc.Weekly Risk Summary & Capital Efficient Trading Techniques - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

What is William Blair’s Forecast for XENE FY2027 Earnings? - Defense World

Aug 14, 2025
pulisher
Aug 14, 2025

Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook - MSN

Aug 14, 2025
pulisher
Aug 13, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 13, 2025
pulisher
Aug 13, 2025

Xenon (XENE) Receives a Buy from RBC Capital - The Globe and Mail

Aug 13, 2025
pulisher
Aug 13, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Receives Buy Rating from Chardan Capital - Defense World

Aug 13, 2025
pulisher
Aug 13, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Royal Bank Of Canada - Defense World

Aug 13, 2025
pulisher
Aug 13, 2025

Xenon Pharmaceuticals Inc. Approaches Psychological Resistance LevelFed Meeting & Daily Stock Momentum Reports - beatles.ru

Aug 13, 2025
pulisher
Aug 13, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up on Analyst Upgrade - Defense World

Aug 13, 2025
pulisher
Aug 13, 2025

Will Xenon Pharmaceuticals Inc. continue its uptrendQuarterly Investment Review & Intraday High Probability Alerts - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

Best data tools to analyze Xenon Pharmaceuticals Inc. stockFree Daily Top Performing Stock Insights - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

TD Cowen Reaffirms Their Buy Rating on Xenon (XENE) - The Globe and Mail

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Completes Patient Recruitment for Phase 3 Study - The Globe and Mail

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Pharmaceuticals: Azetukalner's 2026 Data Readouts and Multi-Indication Launch Potential - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha

Aug 12, 2025
pulisher
Aug 12, 2025

Catalyst Pharmaceuticals shares rise 2.54% intraday after Xenon Pharmaceuticals reports positive Phase 3 study progress and commercial leadership appointment. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Pharmaceuticals shares rise 7.40% intraday after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Pharma Q2 2025 Earnings Preview - MSN

Aug 12, 2025
pulisher
Aug 12, 2025

RBC Capital Adjusts Price Target on Xenon Pharmaceuticals to $55 From $57, Maintains Outperform Speculative Risk Rating - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $57 From $60, Maintains Buy Rating - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Pharmaceuticals shares rise 7.04% premarket after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Compass Pathways shares fall 2.53% premarket after Xenon Pharmaceuticals reports Q2 2025 financial results. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate

Aug 12, 2025
pulisher
Aug 12, 2025

Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Aug 12, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals' Q2 2025: Navigating Contradictions in X-TOLE2 Enrollment, Dosing, and Safety Strategies - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals jumps after massive earnings beat By Investing.com - Investing.com South Africa

Aug 11, 2025
pulisher
Aug 11, 2025

Is a relief rally coming for Xenon Pharmaceuticals Inc. holders5-Year Price Trend Summary and Analysis - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals' Azetukalner: A High-Potential Biotech Catalyst Ahead of 2026 Topline Data - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Transcript : Xenon Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Has Xenon Pharmaceuticals Inc. found a price floorMomentum Prediction Based on AI Backtesting - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals jumps after massive earnings beat - Investing.com

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals Inc. SEC 10-Q Report - TradingView

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals Q2 Loss Widens, CFO Changes Announced - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals' Q2 2025 Earnings: A Catalyst for Neuroscience Innovation and Shareholder Value - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals Q2 Loss Widens - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals: A High-Conviction Play in Neurological Therapeutics with Azetukalner in Late-Stage Development - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Reports Second Quarter 2025 Financial Results & Business Update - GlobeNewswire

Aug 11, 2025
pulisher
Aug 11, 2025

RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN

Aug 11, 2025
pulisher
Aug 11, 2025

Signal strength of Xenon Pharmaceuticals Inc. stock in tech scannersFree Consistent Income Focused Trade List - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Is Xenon Pharmaceuticals Inc. a candidate for recovery playDay Trading Setup Forecast with Trend Model - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Institutional scanner results for Xenon Pharmaceuticals Inc.AI Intraday Market Movement Prediction Tool - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Natixis Advisors LLC - Defense World

Aug 11, 2025
pulisher
Aug 11, 2025

Should I buy Xenon Pharmaceuticals Inc. stock before earningsInvestment Timing Strategy with Market Filters - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Published on: 2025-08-11 01:10:41 - Newser

Aug 11, 2025

Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$36.35
price down icon 0.41%
$86.92
price up icon 0.88%
$26.69
price up icon 0.91%
$127.80
price up icon 0.04%
$113.52
price up icon 0.73%
biotechnology ONC
$321.36
price up icon 3.77%
Kapitalisierung:     |  Volumen (24h):